AU2019205821C1 - G1T38 superior dosage regimes - Google Patents

G1T38 superior dosage regimes Download PDF

Info

Publication number
AU2019205821C1
AU2019205821C1 AU2019205821A AU2019205821A AU2019205821C1 AU 2019205821 C1 AU2019205821 C1 AU 2019205821C1 AU 2019205821 A AU2019205821 A AU 2019205821A AU 2019205821 A AU2019205821 A AU 2019205821A AU 2019205821 C1 AU2019205821 C1 AU 2019205821C1
Authority
AU
Australia
Prior art keywords
compound
cancer
effective amount
administered
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019205821A
Other languages
English (en)
Other versions
AU2019205821A1 (en
AU2019205821B2 (en
Inventor
Andrew BEELEN
Jay Copeland Strum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacosmos Holding AS
Original Assignee
Pharmacosmos Holding AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacosmos Holding AS filed Critical Pharmacosmos Holding AS
Publication of AU2019205821A1 publication Critical patent/AU2019205821A1/en
Application granted granted Critical
Publication of AU2019205821B2 publication Critical patent/AU2019205821B2/en
Priority to AU2024205055A priority Critical patent/AU2024205055A1/en
Publication of AU2019205821C1 publication Critical patent/AU2019205821C1/en
Assigned to PHARMACOSMOS HOLDING A/S reassignment PHARMACOSMOS HOLDING A/S Request for Assignment Assignors: G1 THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2019205821A 2018-01-08 2019-01-08 G1T38 superior dosage regimes Active AU2019205821C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024205055A AU2024205055A1 (en) 2018-01-08 2024-07-24 G1T38 superior dosage regimes

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862614952P 2018-01-08 2018-01-08
US62/614,952 2018-01-08
US201862679575P 2018-06-01 2018-06-01
US62/679,575 2018-06-01
US201962788017P 2019-01-03 2019-01-03
US62/788,017 2019-01-03
PCT/US2019/012720 WO2019136451A1 (en) 2018-01-08 2019-01-08 G1t38 superior dosage regimes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024205055A Division AU2024205055A1 (en) 2018-01-08 2024-07-24 G1T38 superior dosage regimes

Publications (3)

Publication Number Publication Date
AU2019205821A1 AU2019205821A1 (en) 2020-07-09
AU2019205821B2 AU2019205821B2 (en) 2024-07-18
AU2019205821C1 true AU2019205821C1 (en) 2025-02-13

Family

ID=67143921

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019205821A Active AU2019205821C1 (en) 2018-01-08 2019-01-08 G1T38 superior dosage regimes
AU2024205055A Pending AU2024205055A1 (en) 2018-01-08 2024-07-24 G1T38 superior dosage regimes

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024205055A Pending AU2024205055A1 (en) 2018-01-08 2024-07-24 G1T38 superior dosage regimes

Country Status (17)

Country Link
US (3) US11357779B2 (enExample)
EP (1) EP3738084A4 (enExample)
JP (1) JP2021509680A (enExample)
KR (1) KR20200108867A (enExample)
CN (1) CN111837146B (enExample)
AU (2) AU2019205821C1 (enExample)
BR (1) BR112020013915A2 (enExample)
CA (1) CA3087570A1 (enExample)
CO (1) CO2020008825A2 (enExample)
IL (1) IL275708A (enExample)
MX (2) MX2020007312A (enExample)
MY (1) MY205589A (enExample)
PE (1) PE20210121A1 (enExample)
PH (1) PH12020551050A1 (enExample)
RU (1) RU2020123665A (enExample)
SG (1) SG11202005937QA (enExample)
WO (1) WO2019136451A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6430483B2 (ja) * 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
WO2019136451A1 (en) * 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
WO2019199883A1 (en) * 2018-04-09 2019-10-17 G1 Therapeutics, Inc. Treatment of cancers having driving oncogenic mutations
TW202128174A (zh) * 2019-10-09 2021-08-01 美商G1治療公司 失調之纖維母細胞生長因子受體訊息傳遞的癌症之標靶性治療
JP7853532B2 (ja) 2020-05-19 2026-04-30 ファーマコスモス ホールディング エー／エス 医学的障害を治療するためのサイクリン依存性キナーゼ阻害化合物
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
CN116322693A (zh) * 2020-08-13 2023-06-23 辉瑞公司 组合疗法
WO2022161205A1 (zh) * 2021-01-29 2022-08-04 珠海联邦制药股份有限公司 一种含有jak抑制剂或其盐或其晶型的口服制剂及其制备方法和应用
KR20230157379A (ko) * 2021-03-17 2023-11-16 암젠 인크 소토라십 투약 요법
IL310975A (en) * 2021-09-03 2024-04-01 Novartis Ag LOU064 for the treatment of multiple sclerosis
EP4541791A4 (en) * 2022-06-16 2026-06-24 Shionogi & Co Dihydrooxadiazinone compound and pharmaceutical use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006393A1 (en) * 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE298248T1 (de) 1998-04-15 2005-07-15 Brigham & Womens Hospital T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
BRPI0509580A (pt) 2004-03-30 2007-11-27 Pfizer Prod Inc combinações de inibidores de transdução de sinal
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
EP2094682A2 (en) 2006-12-22 2009-09-02 Novartis AG Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
US9259399B2 (en) 2007-11-07 2016-02-16 Cornell University Targeting CDK4 and CDK6 in cancer therapy
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ES2622559T3 (es) 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
WO2010039997A2 (en) 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
AU2009310352A1 (en) 2008-10-01 2010-05-06 The University Of North Carolina At Chapel Hill Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
ES2668874T3 (es) 2009-04-30 2018-05-22 Tel Hashomer Medical Research Infrastructure And Services Ltd. Anticuerpos anti-CEACAM1 y métodos de uso de los mismos
EP3025724B1 (en) 2009-05-13 2018-07-11 The University of North Carolina At Chapel Hill Cyclin dependent kinase inhibitors and methods of use
CN102713618B (zh) 2009-09-16 2015-07-15 新基阿维罗米克斯研究公司 蛋白激酶复合物和抑制剂
US9234192B2 (en) * 2010-02-16 2016-01-12 Novo Nordisk A/S Conjugated proteins
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
EP3205648A1 (en) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US9271988B2 (en) 2011-07-01 2016-03-01 Novartis Ag Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
ES2753614T3 (es) 2011-12-01 2020-04-13 Brigham & Womens Hospital Inc Anticuerpos recombinantes anti-CEACAM1 para terapia contra el cáncer
EP2791132A4 (en) 2011-12-14 2015-08-05 Seragon Pharmaceuticals Inc ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
BR112014014767A2 (pt) 2011-12-16 2017-06-13 Olema Pharmaceuticals Inc novos compostos de benzopirano, composições e usos dos mesmos
EP3216792B1 (en) 2012-03-29 2020-05-27 G1 Therapeutics, Inc. Lactam kinase inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP2015525781A (ja) 2012-07-31 2015-09-07 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の調節
CN104145514B (zh) 2012-08-01 2018-03-13 华为技术有限公司 用于同步的方法、装置及系统
HK1213044A1 (zh) 2012-08-03 2016-06-24 Foundation Medicine, Inc. 人乳头瘤病毒作为肿瘤预後的预测因子
DK3431475T3 (da) 2013-02-21 2021-05-25 Pfizer Faste former af en selektiv CDK4/6-hæmmer
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
CA2906157C (en) * 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
WO2014144596A2 (en) 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US20160361314A1 (en) 2013-08-28 2016-12-15 Novartis Ag Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases
WO2015061407A1 (en) 2013-10-24 2015-04-30 Francis Xavier Tavares Process for synthesis of lactams
US10314842B2 (en) 2013-12-02 2019-06-11 Cornell University Methods for treating B cell proliferative disorders
US11013743B2 (en) 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
RU2670762C2 (ru) 2013-12-31 2018-10-25 Хуаньчжу Фарма Ко., Лтд. Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака
WO2015161283A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
US20160220569A1 (en) * 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
CN106065016B (zh) 2015-04-22 2019-03-12 江苏恒瑞医药股份有限公司 一种周期素依赖性蛋白激酶抑制剂的结晶形式及其制备方法
US20180243304A1 (en) 2015-08-28 2018-08-30 Novartis Ag Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2017193141A1 (en) 2016-05-06 2017-11-09 Siyuan Zhang Prognosis biomarkers and anti-tumor compositions of targeted therapeutic treatments for triple negative breast cancer
WO2017223115A1 (en) 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3541389A1 (en) 2016-11-16 2019-09-25 Pfizer Inc Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
IL317919A (en) 2016-12-05 2025-02-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
WO2018170447A1 (en) 2017-03-16 2018-09-20 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
WO2018183479A1 (en) 2017-03-30 2018-10-04 Dana-Farber Cancer Institute, Inc. Methods for modulating regulatory t cells and immune responses using cdk4/6 inhibitors
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CA3067023A1 (en) 2017-06-12 2018-12-20 Syros Pharmaceuticals, Inc. Compositions and methods for treating cancers with covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
GB201709417D0 (en) 2017-06-14 2017-07-26 Inst Of Cancer Research: Royal Cancer Hospital Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer
TW201904574A (zh) 2017-06-21 2019-02-01 大陸商江蘇恆瑞醫藥股份有限公司 ＳＥＲＤ與ＣＤＫ４／６抑制劑、ＰＩ３Ｋ／ｍＴＯＲ通路抑制劑的用途
CA3066778A1 (en) 2017-06-21 2018-12-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3661519A1 (en) 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
US20200377599A1 (en) 2017-11-30 2020-12-03 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating cancer
WO2019136451A1 (en) * 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006393A1 (en) * 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bisi, JE, et al., "Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors", ONCOTARGET, 8(26), P42343-42358 *
Caira M.R, "Crystalline Polymorphism of Organic Compounds", Design of Organic solids, Weber E et al "ED", Springer, 1998 *
History of Changes for NCT02983071, "G1T38, a CDK4/6 Inhibitor, in Combination with Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advance Metastatic Breast Cancer", January 3, 2018, From www.clinicaltrials.gov - 27-07-2023 *
Singhal, D. et al., Drug polymorphism and dosage form design: a practical perspective, Advanced Drug Delivery Reviews, 2004, Vol. 56, pages 33 *

Also Published As

Publication number Publication date
MX2020007312A (es) 2021-01-08
US20260014160A1 (en) 2026-01-15
CA3087570A1 (en) 2019-07-11
CO2020008825A2 (es) 2020-07-31
CN111837146B (zh) 2024-10-15
CN111837146A (zh) 2020-10-27
US11357779B2 (en) 2022-06-14
US20230149406A1 (en) 2023-05-18
AU2024205055A1 (en) 2024-08-15
BR112020013915A2 (pt) 2020-12-01
EP3738084A4 (en) 2021-11-17
AU2019205821A1 (en) 2020-07-09
MY205589A (en) 2024-10-28
RU2020123665A (ru) 2022-02-10
MX2024013788A (es) 2024-12-06
PH12020551050A1 (en) 2021-08-23
US20200405721A1 (en) 2020-12-31
IL275708A (en) 2020-08-31
KR20200108867A (ko) 2020-09-21
PE20210121A1 (es) 2021-01-19
WO2019136451A1 (en) 2019-07-11
JP2021509680A (ja) 2021-04-01
US12364697B2 (en) 2025-07-22
NZ765617A (en) 2025-10-31
SG11202005937QA (en) 2020-07-29
EP3738084A1 (en) 2020-11-18
AU2019205821B2 (en) 2024-07-18

Similar Documents

Publication Publication Date Title
US12364697B2 (en) G1T38 superior dosage regimes
US12139494B2 (en) Morphic forms of G1T38 and methods of manufacture thereof
EP4153597B1 (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
WO2020206035A1 (en) Treatment of cdk4/6 inhibitor resistant neoplastic disorders
WO2020206034A1 (en) Cell cycle inhibiting compounds for the treatment of medical disorders
WO2019222521A1 (en) Cdk inhibitors for the treatment of neoplastic disorders
EA051409B1 (ru) Преимущественные режимы дозирования g1т38
HK40041180A (en) G1t38 superior dosage regimes
HK40041180B (en) G1t38 superior dosage regimes
EA050245B1 (ru) Соединения, ингибирующие циклинзависимые киназы, для лечения нарушений состояния здоровья
BR112019027967B1 (pt) Forma b cristalina isolada, composição farmacêutica, uso de um composto ou composição, e, processo para produzir forma b cristalina
HK40030270B (en) Morphic forms of git38 and methods of manufacture thereof
HK40030270A (en) Morphic forms of git38 and methods of manufacture thereof
EA041689B1 (ru) Морфологические формы g1t38 и способы их получения

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 21 OCT 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 21 OCT 2024

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PHARMACOSMOS HOLDING A/S

Free format text: FORMER OWNER(S): G1 THERAPEUTICS, INC.